Reviewing 22nd Century Group Inc. (XXII)’s and Allogene Therapeutics Inc. (NASDAQ:ALLO)’s results

Both 22nd Century Group Inc. (NYSEAMERICAN:XXII) and Allogene Therapeutics Inc. (NASDAQ:ALLO) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
22nd Century Group Inc. 26.43M 9.34 7.97M -0.03 0.00
Allogene Therapeutics Inc. N/A 0.00 211.50M 0.00 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for 22nd Century Group Inc. and Allogene Therapeutics Inc.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
22nd Century Group Inc. -30.16% -3.6% -3.4%
Allogene Therapeutics Inc. 0.00% 0% 0%


The Current Ratio of 22nd Century Group Inc. is 10.2 while its Quick Ratio stands at 9.7. The Current Ratio of rival Allogene Therapeutics Inc. is 1.6 and its Quick Ratio is has 1.6. 22nd Century Group Inc. is better equipped to clear short and long-term obligations than Allogene Therapeutics Inc.

Institutional & Insider Ownership

Roughly 30.9% of 22nd Century Group Inc. shares are held by institutional investors while 52.3% of Allogene Therapeutics Inc. are owned by institutional investors. Insiders held 12.38% of 22nd Century Group Inc. shares. Competitively, 21.2% are Allogene Therapeutics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
22nd Century Group Inc. -3.69% 4.91% -19.52% -5.62% -2.89% -5.62%
Allogene Therapeutics Inc. 0.66% 5.31% 4.72% 0% 0% 18.6%

For the past year 22nd Century Group Inc. had bearish trend while Allogene Therapeutics Inc. had bullish trend.


On 5 of the 9 factors Allogene Therapeutics Inc. beats 22nd Century Group Inc.

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The company’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.